Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis.
Home
P D
PD
SCMS-Diabetes Medical School, Newcastle upon Tyne, UK. E-philip.home@newcastle.ac.uk
Pocock
S J
SJ
Beck-Nielsen
H
H